ADVERTISEMENT
Julie Kanter, MD, Talks QoL Outcomes After Lentiglobin Gene Therapy for Sickle Cell Disease
12/15/2020
Dr Kanter, University of Alabama at Birmingham, Birmingham, AL, provides an overview on lentiglobin gene therapy for sickle cell disease, quality of life data from the virtual 2020 ASH Annual Meeting and Exposition, and how measuring outcomes for these patients can be further improved.
